KITE-222

KITE-222 is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy developed by Kite, a Gilead Company. It is engineered to express a CAR that specifically targets C-type lectin-like molecule-1 (CLL-1), also known as C-type lectin domain family 12 member A. CLL-1 is expressed on malignant cells in up to 90% of patients with acute myeloid leukemia (AML) and is restricted to lineage-committed myeloid cells, sparing healthy hematopoietic stem cells. Preclinical studies have shown robust antigen-specific function and the ability of these CAR T cells to clear AML cells in aggressive tumor models. KITE-222 has received FDA Orphan Drug Designation for AML and is currently being evaluated in Phase 1 clinical trials for relapsed/refractory AML[1][4][6]. The therapy uses an engineered autologous cell therapy platform and is administered intravenously.